3,3'-Diindolylmethane suppresses the growth of gastric cancer cells via activation of the Hippo signaling pathway

Oncology Reports

Volumn 30, Issue 5, 2013, Pages 2419-2426

  Li, Xiu Juan ^a   Park, Eun Sung ^b   Park, Man Hee ^c   Kim, Soo Mi ^a  

^a Chonbuk National University Medical School   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Catholic University of Pusan   (South Korea)

Author keywords

3,3' diindolylmethane; Apoptosis; Hippo signaling pathway

Indexed keywords

3,3' DIINDOLYLMETHANE; BINDING PROTEIN; CASPASE 9; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; HIPPO PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROCASPASE 3; PROTEIN KINASE; PROTEIN LATS1; PROTEIN MOB1; PROTEIN P53; PROTEIN YAP; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME SYNTHESIS; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CARCINOGENESIS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; MICE; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885047899     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2717     Document Type: Article

References (49)

1. Kong D, Banerjee S, Huang W, et al: Mammalian target of rapamycin repression by 3,3'-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells. Cancer Res 68: 1927-1934, 2008.
2. Shin HR, Carlos MC and Varghese C: Cancer control in the Asia Pacific region: current status and concerns. Jpn J Clin Oncol 42: 867-881, 2012.
3. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
4. Tan IB, Ng I, Tai WM and Tan P: Understanding the genetic basis of gastric cancer: recent advances. Expert Rev Gastroenterol Hepatol 6: 335-341, 2012.
5. Hoffmann W: Stem cells, self-renewal and cancer of the gastric epithelium. Curr Med Chem 19: 5975-5983, 2012.
6. Cho JY, Lim JY, Cheong JH, et al: Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res 17: 1850-1857, 2011.
7. Hundahl SA, Phillips JL and Menck HR: The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the 'different disease' hypothesis. Cancer 88: 921-932, 2000.
8. Kovoor PA and Hwang J: Treatment of resectable gastric cancer: current standards of care. Exp Rev Anticancer Ther 9: 135-142, 2009.
9. Rausei S, Dionigi G, Rovera F, et al: A decade in gastric cancer curative surgery: evidence of progress (1999-2009). World J Gastrointest Surg 4: 45-54, 2012.
10. Harvey KF, Pfleger CM and Hariharan IK: The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell 114: 457-467, 2003.
11. Harvey K and Tapon N: The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network. Nat Rev Cancer 7: 182-191, 2007.
12. Grusche FA, Richardson HE and Harvey KF: Upstream regulation of the hippo size control pathway. Curr Biol 20: R574-R582, 2010.
13. Harvey KF and Hariharan IK: The hippo pathway. Cold Spring Harb Perspect Biol 4: a011288, 2012.
14. Zeng Q and Hong W: The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. Cancer Cell 13: 188-192, 2008.
15. Edgar BA: From cell structure to transcription: Hippo forges a new path. Cell 124: 267-273, 2006.
16. Zhao B, Li L, Lei Q and Guan KL: The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev 24: 862-874, 2010.
17. Xu ZP, Zhu JS, Zhang Q and Wang XY: A breakdown of the Hippo pathway in gastric cancer. Hepatogastroenterology 58: 1611-1617, 2011.
18. Zhou Z, Zhu JS, Xu ZP and Zhang Q: Lentiviral vector-mediated siRNA knockdown of the YAP gene inhibits growth and induces apoptosis in the SGC7901 gastriccancer cell line. Mol Med Rep 4: 1075-1082, 2011.
19. Min B, Kim MK, Zhang JW, et al: Identification of RUNX3 as a component of the MST/Hpo signaling pathway. J Cell Physiol 227: 839-849, 2012.
20. Yoshihama Y, Izumisawa Y, Akimoto K, et al: High expression of KIBRA in low atypical protein kinase C-expressing gastric cancer correlates with lymphatic invasion and poor prognosis. Cancer Sci 104: 259-265, 2013.
21. Song M, Cheong JH, Kim H, Noh SH and Kim H: Nuclear expression of Yes-associated protein 1 correlates with poor prognosis in intestinal type gastric cancer. Anticancer Res 32: 3827-3834, 2012.
22. Lam-Himlin DM, Daniels JA, Gayyed MF, et al: The hippo pathway in human upper gastrointestinal dysplasia and carcinoma: a novel oncogenic pathway. Int J Gastrointest Cancer 37: 103-109, 2006.
23. Seymour JD, Calle EE, Flagg EW, Coates RJ, Ford ES and Thun MJ; American Cancer Society: Diet Quality Index as a predictor of short-term mortality in the American Cancer Society Cancer Prevention Study II Nutrition Cohort. Am J Epidemiol 157: 980-988, 2003.
24. Gao N, Cheng S, Budhraja A, et al: 3,3'-Diindolylmethane exhibits antileukemic activity in vitro and in vivo through a Akt-dependent process. PloS One 7: e31783, 2012.
25. Grose KR and Bjeldanes LF: Oligomerization of indole-3-carbinol in aqueous acid. Chem Res Toxicol 5: 188-193, 1992.
26. Keck AS and Finley JW: Cruciferous vegetables: cancer protective mechanisms of glucosinolate hydrolysis products and selenium. Integr Cancer Ther 3: 5-12, 2004.
27. Banerjee S, Wang Z, Kong D and Sarkar FH: 3,3'-Diindolyl-methane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res 69: 5592-5600, 2009.
28. Kim SJ, Lee JS and Kim SM: 3,3'-Diindolylmethane suppresses growth of human esophageal squamous cancer cells by G1 cell cycle arrest. Oncol Rep 27: 1669-1673, 2012.
29. Ali S, Banerjee S, Ahmad A, El-Rayes BF, Philip PA and Sarkar FH: Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. Mol Cancer Ther 7: 1708-1719, 2008.
30. Chinnakannu K, Chen D, Li Y, et al: Cell cycle-dependent effects of 3,3'-diindolylmethane on proliferation and apoptosis of prostate cancer cells. J Cell Physiol 219: 94-99, 2009.
31. Bhuiyan MM, Li Y, Banerjee S, et al: Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res 66: 10064-10072, 2006.
32. Li Y, Chinni SR and Sarkar FH: Selective growth regulatory and pro-apoptotic effects of DIM is mediated by AKT and NF-kappaB pathways in prostate cancer cells. Front Biosci 10: 236-243, 2005.
33. Nachshon-Kedmi M, Fares FA and Yannai S: Therapeutic activity of 3,3'-diindolylmethane on prostate cancer in an in vivo model. Prostate 61: 153-160, 2004.
34. Rahman KW and Sarkar FH: Inhibition of nuclear translocation of nuclear factor-κB contributes to 3,3'-diindolylmethane-induced apoptosis in breast cancer cells. Cancer Res 65: 364-371, 2005.
35. Abdelrahim M, Newman K, Vanderlaag K, Samudio I and Safe S: 3,3'-diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5. Carcinogenesis 27: 717-728, 2006.
36. Carter TH, Liu K, Ralph W Jr, et al: Diindolylmethane alters gene expression in human keratinocytes in vitro. J Nutr 132: 3314-3324, 2002.
37. Azmi AS, Ahmad A, Banerjee S, Rangnekar VM, Mohammad RM and Sarkar FH: Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3,3' diindolylmethane (DIM). Pharm Res 25: 2117-2124, 2008.
38. Kim SJ, Chung MJ, Kim JS, et al: Deciphering the role of paclitaxel in the SKGT4 human esophageal adenocarcinoma cell line. Int J Oncol 39: 1587-1591, 2011.
39. Dammann R, Li C, Yoon JH, Chin PL, Bates S and Pfeifer GP: Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25: 315-319, 2000.
40. Dammann R, Schagdarsurengin U, Seidel C, et al: The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol 20: 645-663, 2005.
41. Guo C, Zhang X and Pfeifer GP: The tumor suppressor RASSF1A prevents dephosphorylation of the mammalian STE20-like kinases MST1 and MST2. J Biol Chem 286: 6253-6261, 2011.
42. Chen Y, Xu J, Jhala N, et al: Fas-mediated apoptosis in cholangiocarcinoma cells is enhanced by 3,3'-diindolylmethane through inhibition of AKT signaling and FLICE-like inhibitory protein. Am J Pathol 169: 1833-1842, 2006.
43. Saucedo LJ and Edgar BA: Filling out the Hippo pathway. Nat Rev Mol Cell Biol 8: 613-621, 2007.
44. Burbee DG, Forgacs E, Zöchbauer-Müller S, et al: Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 93: 691-699, 2001.
45. Agathanggelou A, Cooper WN and Latif F: Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 65: 3497-3508, 2005.
46. Tommasi S, Dammann R, Zhang Z, et al: Tumor susceptibility of Rassf1a knockout mice. Cancer Res 65: 92-98, 2005.
47. Vichalkovski A, Gresko E, Cornils H, Hergovich A, Schmitz D and Hemmings BA: NDR kinase is activated by RASSF1A/MST1 in response to Fas receptor stimulation and promotes apoptosis. Curr Biol 18: 1889-1895, 2008.
48. Guo C, Tommasi S, Liu L, Yee JK, Dammann R and Pfeifer GP: RASSF1A is part of a complex similar to the Drosophila Hippo/Salvador/Lats tumor-suppressor network. Curr Biol 17: 700-705, 2007.
49. Matallanas D, Romano D, Yee K, et al: RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol Cell 27: 962-975, 2007.